A Randomized, Parallel-group, Double-blind, Double-dummy, Active-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

Trial Profile

A Randomized, Parallel-group, Double-blind, Double-dummy, Active-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTEROID 5
  • Sponsors Bayer
  • Most Recent Events

    • 29 Aug 2017 Accrding to a Bayer media release, first U.S. patient has been enrolled.
    • 03 Jul 2017 According to a Bayer media release, the first patient has been enrolled in this trial.
    • 04 Jun 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top